Xeris Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Xeris Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Xeris Pharmaceuticals: 14 sponsored US clinical trials, none currently recruiting.
Xeris Pharmaceuticals sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 4 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypoglycemia, with 3 trials.
Top-decile sponsor footprint
Xeris Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
NCT05823012
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
NCT04074317
Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
NCT03770637
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
NCT03738865
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
NCT03490942
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
NCT03439072
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
NCT03091673
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
NCT02656069
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
NCT02937558
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
NCT02733588
G-Pen™ for Hypoglycemia Rescue in T1D Patients
NCT02423980
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
NCT02081001
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
NCT02081014
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
NCT01972152
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 10 |
| Phase 3 | 4 |
How the Xeris Pharmaceuticals early-phase archive is shaped
14 indexed studies, none listed as recruiting (0% open); 13 completed (93%).
Phase mix: 4 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Hypoglycemia (3 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Xeris Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Xeris Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Xeris Pharmaceuticals page
14 registered trials is a research-attention snapshot, not an endorsement of Xeris Pharmaceuticals or any single study.
- None of Xeris Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypoglycemia is the condition Xeris Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypoglycemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Xeris Pharmaceuticals pipeline card: 14 registered trials from official public datasets.Report a data error.